会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 7. 发明公开
    • PHENYLALKYL-IMIDAZOLE-BISPHOSPHONATE COMPOUNDS
    • 苯基 - 咪唑 - 二膦酸酯化合物
    • EP2382223A1
    • 2011-11-02
    • EP09806020.5
    • 2009-12-21
    • Novartis AG
    • COTESTA, SimonaJAHNKE, WolfgangRONDEAU, Jean-MichelWEILER, SvenWIDLER, Leo
    • C07F9/6506A61K31/663
    • C07F9/65061
    • (Unsubstituted or substituted phenyl)-alkyl-substituted [(imidazol-1-yl)-1-hydroxy-1- phosphono-ethyl]-phosρhonic, as well as methods or processes for their manufacture, their use in the manufacture of pharmaceutical formulations, their use in the treatment of diseases, methods of using them in the treatment of diseases, pharmaceutical formulations encompassing them and/or the compounds for use in the treatment of diseases, are disclosed. The compounds are able to inhibit excessive or inappropriate bone resorption. The compounds are of the formula (I), wherein one of R
      1 and R
      2 are as defined in the specification, and can be in free form, in the form of an ester, and/or of a salt.
    • (未取代的或取代的苯基) - 烷基取代的[(咪唑-1-基)-1-羟基-1-膦酰基乙基] - 膦酸,以及它们的制备方法或方法,它们在制备药物制剂中的用途 ,它们在治疗疾病中的用途,使用它们治疗疾病的方法,包含它们的药物制剂和/或用于治疗疾病的化合物。 这些化合物能够抑制过度或不适当的骨吸收。 所述化合物是式(I)的化合物,其中R 1和R 2中的一个如说明书中所定义,并且可以以游离形式,以酯和/或盐的形式存在。
    • 9. 发明公开
    • C2-C5-ALKYL-IMIDAZOLE-BISPHOSPHONATES
    • C2-C5烷基咪唑双膦酸盐
    • EP2225252A1
    • 2010-09-08
    • EP08854485.3
    • 2008-11-26
    • Novartis AG
    • WEILER, SvenWIDLER, LeoRONDEAU, Jean-MichelCOTESTA, SimonaJAHNKE, Wolfgang
    • C07F9/6506A61K31/663A61P19/00
    • C07F9/65061
    • C2-C5-Alkyl-substituted [(imidazol-1 -yl)-1-hydroxy-1-phosphono-ethyl]-phosphonic acids, as well as methods or processes for their manufacture, their use in the manufacture of pharmaceutical formulations, their use in the treatment of diseases, methods of using them in the treatment of diseases, pharmaceutical formulations encompassing them and/or the compounds for use in the treatment of diseases, are described. The compounds are able to inhibit excessive or inappropriate bone resorption and for the treatment of other diseases which are caused by excessive prenylation of target proteins, such as Hutchinson-Gilford progeria syndrome. The compounds are of the formula (I), wherein one of R1 and R2 is hydrogen and the other is C2-C5-alkyl that is branched or unbranched, and can be in free form, in the form of an ester, and/or of a salt.
    • C 2 -C 5 - 烷基取代的[(咪唑-1-基)-1-羟基-1-膦酰基乙基]膦酸,以及其制备方法或方法,其在制备药物制剂中的用途,它们的 用于治疗疾病,使用它们治疗疾病的方法,包含它们的药物制剂和/或用于治疗疾病的化合物。 这些化合物能够抑制过度或不适当的骨吸收,并用于治疗由靶蛋白过度异戊二烯化引起的其他疾病,如Hutchinson-Gilford早衰综合征。 所述化合物是式(I)的化合物,其中R 1和R 2中的一个是氢并且另一个是支链或非支链的C 2 -C 5 - 烷基,并且可以以酯的形式呈游离形式,和/或 的盐。